Published in Health and Medicine Week, July 18th, 2005
The two compounds are designated BL-2030, a soluble receptor that targets cancer cells that will be developed first for the treatment of prostate cancer, and BL-2040, a small molecule for the treatment of hypertension, obesity, and metabolic syndrome.
The worldwide exclusive license for the development of BL-2030 was signed with BioRap Technologies, a private company established to manage the commercialization of intellectual property developed by members of the Rappaport Family Institute for Research in the Medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.